New hope for liver cancer patients who failed immunotherapy?
Disease control
Recruiting now
This study tests a new drug called AST-3424 for people with a specific type of advanced liver cancer that has gotten worse after immunotherapy. The trial compares AST-3424 to another standard drug, regorafenib, to see which helps people live longer. About 75 participants will rec…
Phase: PHASE2 • Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. • Aim: Disease control
Last updated May 17, 2026 04:13 UTC